BLA 020280 · Pharmacia
Genotropin Preservative Free
Somatropin · Injection
Last checked: Nov 20, 2026Latest source record: Jul 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Aug 24, 1995
Approved uses
6
Original approval plus efficacy supplements
Registered trials
540
176 Phase 3, 31 recruiting
FAERS reports
53,357
11,105 serious, 900 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 4, 2026.
GENOTROPIN is a recombinant human growth hormone indicated for: • Pediatric: Treatment of children with growth failure due to growth hormone deficiency (GHD), Prader-Willi syndrome, Small for Gestational Age, Turner syndrome, and Idiopathic Short Stature ( 1.1 ) • Adult: Treatment of adults with either adult onset or childhood onset GHD ( 1.2 ) 1.1 Pediatric Patients GENOTROPIN is indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone. GENOTROPIN is indicated for the treatment of pediatric patients who have growth failure due to Prader-Willi syndrome (PWS). The diagnosis of PWS should be confirmed by appropriate genetic testing [see Contraindications (4) ] . GENOTROPIN is indicated for the treatment of growth failure in pediatric patients born small for gestational age (SGA) who fail to manifest catch-up growth by age 2 years. GENOTROPIN is indicated for the treatment of growth failure associated with Turner syndrome. GENOTROPIN is indicated for the treatment of idiopathic short stature (ISS), also called non-growth hormone-deficient short stature, defined by height standard deviation score (SDS) ≤-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means. 1.2 Adult Patients GENOTROPIN is indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency who meet either of the following two criteria: Adult Onset (AO): Patients who have growth hormone deficiency, either alone or associated with multiple hormone deficiencies...
Mechanism: In vitro, preclinical, and clinical tests have demonstrated that GENOTROPIN lyophilized powder is therapeutically equivalent to human growth hormone of pituitary origin and achieves similar pharmacokinetic profiles in normal adults. In pediatric patients who have growth hormone deficiency (GHD), have Prader-Willi syndrome (PWS), were born small for gestational age (SGA), have Turner syndrome (TS), or have Idiopathic short stature (ISS), treatment with GENOTROPIN stimulates linear growth. In patients with GHD or PWS, treatment with GENOTROPIN also normalizes concentrations of IGF-I...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 12, 2008 Supplement 60 · Efficacy LetterLabelSummary Review
- Apr 27, 2006 Supplement 49 · Efficacy LabelLetterReview
- Jul 25, 2001 Supplement 31 · Efficacy · priority review LabelReviewLetter
- Jun 20, 2000 Supplement 23 · Efficacy · priority review Letter
- Oct 31, 1997 Supplement 8 · Efficacy Review
- Aug 24, 1995 Original approval · Type 5 - New Formulation or New Manufacturer
13 products under this application
- GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 1.6MG/VIAL · INJECTABLE, INJECTION · Prescription
- GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 0.6MG/VIAL · INJECTABLE, INJECTION · Prescription
- GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 0.2MG/VIAL · INJECTABLE, INJECTION · Prescription
- GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 1MG/VIAL · INJECTABLE, INJECTION · Prescription
- GENOTROPIN · SOMATROPIN 5.8MG/VIAL · INJECTABLE, INJECTION · Prescription
- GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 1.8MG/VIAL · INJECTABLE, INJECTION · Prescription
- GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 1.5MG/VIAL · INJECTABLE, INJECTION · Discontinued
- GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 1.4MG/VIAL · INJECTABLE, INJECTION · Prescription
- GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 0.4MG/VIAL · INJECTABLE, INJECTION · Prescription
- GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 1.2MG/VIAL · INJECTABLE, INJECTION · Prescription
- GENOTROPIN · SOMATROPIN 13.8MG/VIAL · INJECTABLE, INJECTION · Prescription
- GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 2MG/VIAL · INJECTABLE, INJECTION · Prescription
- GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 0.8MG/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Somatropin" as an intervention, any sponsor and status, largest first.
- Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in ChildrenStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT03290235 · 1,500 participants (planned) · Start Mar 1, 2017 · Primary completion Oct 2020
Drug: PEG-somatropin · For: Growth Retardation
Sites: Wuhan, China
- Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and RehabilitationPivotal-lookingTerminated
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00675714 · 1,126 participants · Start Jan 2004 · Primary completion Sep 2018
Drug: Humatrope; Ketoconazole and 5 more · For: Burns
Sites: Galveston, Texas
- Current Status of Islet Alpha Cell Function in Patients with Type 2 DiabetesPivotal-lookingRecruiting
Nanjing First Hospital, Nanjing Medical UniversityAcademic, hospital or other
NCT06825182 · 1,000 participants (planned) · Start Nov 7, 2024 · Primary completion Aug 1, 2025
Drug: Outpatient newly diagnosed type 2 diabetes subjects; Inpatient newly diagnosed type 2 diabetes subjects · For: Type 2 Diabetes Mellitus
Sites: Nanjing, China
- Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone DeficiencyStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT03249480 · 900 participants (planned) · Start Jan 2015 · Primary completion Aug 2017
Drug: PEG-somatropin · For: Growth Hormone Deficiency
Sites: Hefei, China; Fuzhou, China; Guangzhou, China · 28 sites in all
- Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency ChildrenStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT02314676 · 900 participants (planned) · Start Nov 2014 · Primary completion Jul 2017
Drug: PEG-somatropin · For: Dwarfism, Pituitary
Sites: Wuhu, China; Hangzhou, China
- Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone DeficiencyPivotal-lookingStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT02908958 · 900 participants (planned) · Start Nov 2014 · Primary completion Jun 2017
Drug: PEG-somatropin; PEG-somatropin · For: Growth Hormone Deficiency
Sites: Hefei, China; Wuhu, China; Xiamen, China · 22 sites in all
- The Effect of Somatropin Treatment in Adult Patients on Chronic DialysisPivotal-lookingTerminated
Novo Nordisk A/SNovo Nordisk (NVO)
NCT00503698 · 712 participants · Start Jul 2007 · Primary completion Dec 2008
Drug: somatropin; placebo · For: Chronic Kidney Disease; End-Stage Renal Disease
Sites: Alexander City, Alabama; Birmingham, Alabama; Madison, Alabama · 381 sites in all
- Effect of GH Supplementation on the Blastocyst Euploid Rate in AMA Patients--A Retrospective Cohort StudyPivotal-lookingCompleted
ShangHai Ji Ai Genetics & IVF InstituteAcademic, hospital or other
NCT05574894 · 692 participants · Start Jan 1, 2021 · Primary completion Jun 30, 2022
Drug: Growth hormone; GnRH antagonist · For: Growth Hormone; Advanced Maternal Age; PGT-A
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug dose omission by device18,613
- device leakage9,818
- device breakage8,090
- device mechanical issue7,703
- device information output issue7,074
- device issue5,025
- wrong technique in device usage process4,667
- device use error3,272
- poor quality device used3,103
- device physical property issue2,983
- device use issue2,625
- device delivery system issue2,349
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 220 |
| 2005 | 196 |
| 2006 | 224 |
| 2007 | 246 |
| 2008 | 187 |
| 2009 | 317 |
| 2010 | 563 |
| 2011 | 493 |
| 2012 | 1,581 |
| 2013 | 489 |
| 2014 | 557 |
| 2015 | 733 |
| 2016 | 921 |
| 2017 | 1,186 |
| 2018 | 1,911 |
| 2019 | 1,657 |
| 2020 | 1,894 |
| 2021 | 3,374 |
| 2022 | 5,194 |
| 2023 | 8,591 |
| 2024 | 9,365 |
| 2025 | 8,370 |
| 2026 | 5,088 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Genotropin (Somatropin)
2024 spending
$26.8M
Beneficiaries
1,495
11,033 claims
Per beneficiary
$17,930
$625.62 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $18,270,051 |
| 2021 | $22,168,193 |
| 2022 | $23,852,204 |
| 2023 | $27,196,427 |
| 2024 | $26,804,746 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study.
Deal CL, Steelman J, Vlachopapadopoulou E, et al. · J Clin Endocrinol Metab 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency.
Kildemoes RJ, Hollensen C, Biller BMK, et al. · Eur J Endocrinol 2022 · Clinical Trial
- Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.
Thornton PS, Maniatis AK, Aghajanova E, et al. · J Clin Endocrinol Metab 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency: a cross-sectional survey of physicians from the global phase 3 study.
Gomez R, Lamoureux R, Turner-Bowker DM, et al. · Front Endocrinol (Lausanne) 2023 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Efficacy and safety of Valtropin in the treatment of short stature in girls with Turner's syndrome.
Peterkova V, Savoy C, Bezlepkina O, et al. · J Pediatr Endocrinol Metab 2004 · Clinical Trial, Clinical Trial, Phase III
- Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results.
Maniatis AK, Casella SJ, Nadgir UM, et al. · J Clin Endocrinol Metab 2022 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
Sponsor: Pfizer · Also marketed as Genotropin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.